{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:04:55Z","timestamp":1761894295104,"version":"build-2065373602"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Circulating exosomal miRNAs have emerged as important tools for liquid biopsy in cancer diagnosis and prognosis prediction. This project establishes a plasma exosomal miRNA-based system for diagnosing multiple myeloma(MM) and evaluating patient prognosis, aiming to provide novel strategies for diagnosis and early warning in high-risk MM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study prospectively collected plasma samples and clinical data of newly diagnosed multiple myeloma (NDMM) patients and healthy controls (HCs). Plasma samples were obtained in MM patients before the administration of any chemotherapy. The study comprises three stages to identify plasma exosomal miRNAs associated with the diagnosis and prognosis of MM. In the screening stage, next-generation sequencing of plasma circulating exosomes was performed in 17 NDMM patients and 8 HCs to screen the candidate differentially expressed miRNAs. We further investigated a testing stage of 80 individuals (including 60 NDMM patients and 20 HCs) and a verification stage of 130 NDMM through qPT-PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Utilizing a testing cohort of 60 newly diagnosed MM cases, we developed a diagnostic model based on six miRNAs (hsa-miR-192-5p, hsa-miR-10a-5p, hsa-miR-10b-3p, hsa-miR-148a-3p, hsa-miR-193b-5p, hsa-miR-483-3p) achieving an AUC of 0.94, sensitivity of 0.88, and specificity of 0.94. In a validation cohort of 130 MM patients, we developed a prognostic nomogram that amalgamated the expression levels of three key exosomal miRNAs (hsa-miR-193b-5p, miR-483-3p, and let-7b-5p) with critical clinical variables, which exhibits superior performance compared to the ISS staging system. This integrative model effectively predicted 1-, 3-, and 5-year survival probabilities, thereby stratifying patients into distinct risk categories for enhanced clinical decision-making and personalized follow-up strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This research validates the diagnostic and prognostic utility of exosomal miRNA models in MM, emphasizing their discriminative and predictive capabilities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1659708","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:13Z","timestamp":1761888253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and prognostic prediction of high-risk multiple myeloma by exosomal microRNA"],"prefix":"10.3389","volume":"15","author":[{"given":"Ying","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xushu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caigang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.10.003","article-title":"Recent advances in targeted drug delivery systems for multiple myeloma","volume":"376","author":"Pant","year":"2024","journal-title":"J Controlled release"},{"key":"B2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-024-01115-6","article-title":"A roadmap towards improving outcomes in multiple myeloma","volume":"14","author":"Mohty","year":"2024","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240966","article-title":"Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling","volume":"13","author":"Banerjee","year":"2023","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01217","article-title":"Identification of high-Risk multiple myeloma with a plasma cell leukemia-Like transcriptomic profile","volume":"40","author":"Hofste Op Bruinink","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280566","article-title":"Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma","volume":"108","author":"Schavgoulidze","year":"2023","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15086","DOI":"10.1038\/ncomms15086","article-title":"Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates","volume":"8","author":"Kis","year":"2017","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0482","article-title":"MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology","volume":"13","author":"Dutta","year":"2023","journal-title":"Cancer Discov"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.07.009","article-title":"Extracellular vesicle and particle biomarkers define multiple human cancers","volume":"182","author":"Hoshino","year":"2020","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01040","article-title":"Circulating tumor cell burden as a component of staging in multiple myeloma: ready for prime time","volume":"40","author":"Chakraborty","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-022-01509-9","article-title":"Exosomes as a new frontier of cancer liquid biopsy","volume":"21","author":"Yu","year":"2022","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/d41573-020-00220-y","article-title":"Exosome-based candidates move into the clinic","volume":"20","author":"Cully","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-017-0718-4","article-title":"Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts","volume":"16","author":"Yang","year":"2017","journal-title":"Mol Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/bjh.17734","article-title":"MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients","volume":"195","author":"Rinaldi","year":"2021","journal-title":"Br J haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12943-018-0897-7","article-title":"Effect of exosomal miRNA on cancer biology and clinical applications","volume":"17","author":"Sun","year":"2018","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.01.046","article-title":"Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment","volume":"30","author":"Xu","year":"2022","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-018-0579-3","article-title":"Exosomal miRNAs in hepatocellular carcinoma development and clinical responses","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100647","DOI":"10.1016\/j.drup.2019.100647","article-title":"Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance","volume":"47","author":"Vasconcelos","year":"2019","journal-title":"Drug resistance updates: Rev commentaries antimicrobial Anticancer chemother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/0471143030.cb0322s30","article-title":"Isolation and characterization of exosomes from cell culture supernatants and biological fluids","author":"Th\u00e9ry","year":"2006","journal-title":"Curr Protoc Cell Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111277","DOI":"10.1016\/j.intimp.2023.111277","article-title":"Development of a nomogram prognostic model for early Grade \u2265 3 infection in newly diagnosed multiple myeloma based on immunoparesis","volume":"126","author":"Zhang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2014.12.015","article-title":"Clinical implications of immune paresis in symptomatic multiple myeloma patients","volume":"35","author":"Zhou","year":"2014","journal-title":"Zhonghua xue ye xue za zhi=Zhonghua xueyexue zazhi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/cells10030559","article-title":"Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma","volume":"10","author":"Algar\u00edn","year":"2021","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283058","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.074","article-title":"Exosome-based liquid biopsies in cancer: opportunities and challenges","volume":"32","author":"Yu","year":"2021","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.093500","article-title":"Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"99","author":"Kubiczkova","year":"2014","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.06.010","article-title":"Secreted monocytic miR-150 enhances targeted endothelial cell migration","volume":"39","author":"Zhang","year":"2010","journal-title":"Mol Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2011.12.001","article-title":"Secreted microRNAs: a new form of intercellular communication","volume":"22","author":"Chen","year":"2012","journal-title":"Trends Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01005-8","article-title":"Circulating non-coding RNA biomarkers of endocrine tumours","volume":"20","author":"Butz","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1575468","DOI":"10.1155\/2019\/1575468","article-title":"Potential relationship between clinical significance and serum exosomal miRNAs in patients with multiple myeloma","volume":"2019","author":"Zhang","year":"2019","journal-title":"BioMed Res Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv387","article-title":"The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA","volume":"43","author":"Segalla","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078644","article-title":"Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells","volume":"9","author":"Zhao","year":"2014","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12032-014-0219-x","article-title":"Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma","volume":"31","author":"Qu","year":"2014","journal-title":"Med Oncol (Northwood London England)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.862524","article-title":"Exosomal miR-483-5p in bone marrow mesenchymal stem cells promotes Malignant progression of multiple myeloma by targeting TIMP2","volume":"10","author":"Gu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202552","article-title":"Silencing of miR-483-5p alleviates postmenopausal osteoporosis by targeting SATB2 and PI3K\/AKT pathway","volume":"13","author":"Zhao","year":"2021","journal-title":"Aging"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12320","article-title":"MiR-483-5p downregulation contributed to cell proliferation, metastasis, and inflammation of clear cell renal cell carcinoma","volume":"37","author":"Wang","year":"2021","journal-title":"Kaohsiung J Med Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.05.032","article-title":"The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p","volume":"44","author":"Wei","year":"2019","journal-title":"EBioMedicine"},{"key":"B45","article-title":"The fundamental role of miR-10b in metastatic cancer","volume":"8","author":"Sheedy","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2068873","article-title":"Identification of key genes and miRNA-mRNA regulatory networks associated with bone marrow immune microenvironment regulations in multiple myeloma by integrative bioinformatics analysis","volume":"27","author":"Tuerxun","year":"2022","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24669","article-title":"A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells","volume":"229","author":"Leotta","year":"2014","journal-title":"J Cell Physiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28368","article-title":"miR-193: A new weapon against cancer","volume":"234","author":"Khordadmehr","year":"2019","journal-title":"J Cell Physiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12385","article-title":"MIBlood-EV: Minimal information to enhance the quality and reproducibility of blood extracellular vesicle research","volume":"12","author":"Lucien","year":"2023","journal-title":"J extracellular vesicles"},{"key":"B50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.critrevonc.2019.06.005","article-title":"Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology","volume":"141","author":"Ponti","year":"2019","journal-title":"Crit Rev oncology\/hematology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2017.02.029","article-title":"Circulating serum microRNA as diagnostic biomarkers for multiple myeloma","volume":"25","author":"Xu","year":"2017","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-160158","article-title":"Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum","volume":"18","author":"Shen","year":"2017","journal-title":"Cancer biomarkers: section A Dis Markers"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2016.1132627","article-title":"The potential diagnostic power of extracellular vesicle analysis for multiple myeloma","volume":"16","author":"Canella","year":"2016","journal-title":"Expert Rev Mol diagnostics"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.91","article-title":"Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial","volume":"52","author":"Huhn","year":"2017","journal-title":"Bone marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.325","article-title":"Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma","volume":"31","author":"Qin","year":"2017","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1659708\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:16Z","timestamp":1761888256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1659708\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":56,"alternative-id":["10.3389\/fonc.2025.1659708"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1659708","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1659708"}}